Base:prevent preclinical drug development program: preclinical efficacy & intermediate biomarkers task order: targeting STAT3 to prevent hepatocellular carcinoma (HCC) associated with non-alcoholic…
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $840,820
Award facts
- Opportunity
- Contract value 100% obligated
- $840,820.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$2,676 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $843,496 |
About this award
This is a delivery order awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) under the "PREVENT Preclinical Drug Development Program (PREVENT)" Indefinite Delivery Contract (IDC). The delivery order, valued at $840,820.00, is for a project titled "TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)". The project is focused on preclinical efficacy and biomarker evaluation for preventing hepatocellular carcinoma associated with non-alcoholic steatohepatitis. This delivery order does not have a small business set-aside designation. MD Anderson, as a child entity of the University of Texas System, is a premier academic cancer research institution with extensive expertise in federally funded medical research.
Description
Base:prevent preclinical drug development program: preclinical efficacy & intermediate biomarkers task order: targeting STAT3 to prevent hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (nash)
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on June 1, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $840,820 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award